|1.||Dauphin, François: 1 article (01/2009)|
|2.||Da Silva Costa, Virginie: 1 article (01/2009)|
|3.||Boulouard, Michel: 1 article (01/2009)|
|4.||Duchatelle, Pascal: 1 article (01/2009)|
|5.||Gil-Bea, F J: 1 article (10/2008)|
|6.||Chuang, T T: 1 article (10/2008)|
|7.||Ramirez, M J: 1 article (10/2008)|
|8.||Marcos, B: 1 article (10/2008)|
|9.||Finn, David P: 1 article (08/2007)|
|10.||Fone, Kevin C F: 1 article (08/2007)|
|1.||Schizophrenia (Dementia Praecox)
04/01/2002 - "Effects of the 5-HT(6) receptor antagonist, SB-271046, in animal models for schizophrenia."
10/01/2008 - "These data suggest a potential therapeutic role of 5-HT6 receptor antagonists such as SB-271046, alone or in combination with galanthamine, in the treatment of cognitive dysfunction, such as those seen in Alzheimer's disease and schizophrenia."
04/01/2002 - "We studied the effect of SB-271046 [5-chloro-N-(4-methoxy-3-piperazin-1-yl-phenyl)-3-methyl-2-benzothiophenesulfonamide], a specific 5-HT(6) receptor antagonist, in three models for the positive symptoms of schizophrenia---D-amphetamine-induced hyperactivity, and D-amphetamine- or phencyclidine (PCP)-disrupted prepulse inhibition (PPI). "
08/13/2007 - "These data provide the first evidence for 5-HT(6) receptor-mediated regulation of nociception and hypothalamo-pituitary-adrenal axis activity in a model of persistent pain although effects on locomotor activity demand that the putative antinociceptive effect of SB-271046 be interpreted with some caution."
|4.||Memory Disorders (Memory Loss)
|5.||Amnesia (Dissociative Amnesia)
|1.||serotonin 6 receptor
|3.||Phencyclidine (Angel Dust)